# US 2022/0007637 A1 · Method of disc decompression and disc supplementation

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0007637 A1
- Document ID: US20220007637A1
- Status: Published application
- Kind: A1
- Application number: 17/487,618
- Filed: 2021-09-28
- Published: 2022-01-13
- Earliest claimed: 2016-12-20
- Assignees: Vivex Biologics Group, Inc.
- Applicants: Vivex Biologics Group, Inc.
- Inventors: Timothy Ganey; Stanley Golovac
- Web page: https://patentgrep.com/patent/US20220007637A1

## CPC

- A01N 1/162: Temperature processes, e.g. following predefined temperature changes over time
- A61L 27/3604: {characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel}
- A01N 1/125: Freeze protecting agents, e.g. cryoprotectants or osmolarity regulators
- A01N 1/128: Chemically defined matrices for immobilising, holding or storing living parts, e.g. alginate gels; Chemically altering living parts, e.g. by cross-linking
- A61K 35/32: Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
- A61L 27/365: {Bones}
- A61L 27/3658: {Intervertebral discs (mechanical aspects and structures of intervertebral discs A61F2/442)}
- A61L 27/3687: {characterised by the use of chemical agents in the treatment, e.g. specific enzymes, detergents, capping agents, crosslinkers, anticalcification agents}
- A61L 27/3691: {characterised by physical conditions of the treatment, e.g. applying a compressive force to the composition, pressure cycles, ultrasonic/sonication or microwave treatment, lyophilisation}
- A61L 27/3821: {Bone-forming cells, e.g. osteoblasts, osteocytes, osteoprogenitor cells}
- A61L 27/3834: {Cells able to produce different cell types, e.g. hematopoietic stem cells, mesenchymal stem cells, marrow stromal cells, embryonic stem cells}
- A61L 27/3856: {Intervertebral discs (mechanical aspects and structures of intervertebral discs A61F2/442)}
- A61L 27/50: Materials characterised by their function or physical properties {, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials}
- A01N 1/16: Physical preservation processes
- A61L 2400/06: Flowable or injectable implant compositions
- A61L 2430/38: for reconstruction of the spine, vertebrae or intervertebral discs
- A01N: PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF (preservation of food or foodstuff A23); BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES (preparations for medical, dental or toiletry purposes which kill or prevent the growth or proliferation of unwanted organisms A61K); PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

A method for damaged viable disc regeneration has the steps of identifying the damaged viable disc and inserting a cannula via Kambin's Triangle to an edge of an outer annulus of the disc; introducing a trocar into the cannula and penetrating the trocar into a central region of nucleus pulposus; removing a tissue biopsy sample from the nucleus pulposus for pathology and removing additional degenerative tissue from the central region to create a void or space; withdrawing the trocar from the cannula and inserting a needle into the cannula to the void or space; and injecting a regenerative disc material through the needle into the void or space to repair the damaged disc.

## Claims

### Claim 1

A method for damaged viable disc regeneration comprises the steps of:
identifying the damaged viable disc and inserting a cannula via Kambin's Triangle to an edge of an outer annulus of the disc;
introducing a trocar into the cannula and penetrating the trocar into a central region of nucleus pulposus;
removing a tissue biopsy sample from the nucleus pulposus for pathology and removing additional degenerative tissue from the central region to create a void or space;
withdrawing the trocar from the cannula and inserting a needle into the cannula to the void or space; and
injecting a regenerative disc material through the needle into the void or space to repair the damaged disc.

### Claim 2 (depends on 1)

The method of claim 1, wherein the removed tissue biopsy is evaluated for degenerative conditions.

### Claim 3 (depends on 1)

The method of claim 1, wherein the step of removing the additional degenerative tissue decompresses the damaged disc.

### Claim 4 (depends on 1)

The method of claim 1, wherein the step of injecting the regenerative disc material at least partially fills the void or space with a volume of material sufficient to re-establish a height of the disc.

### Claim 5 (depends on 1)

The method of claim 1 further comprises the step of removing the needle and injecting a glue or fibrin material into the cannula for sealing any opening in the repaired disc to seal and prevent leakage.

### Claim 6 (depends on 1)

The method of claim 1, wherein the regenerative disc material is a flowable material that passes through a small gauge needle.

### Claim 7 (depends on 6)

The method of claim 6, wherein the regenerative disc material includes dried nucleus pulposus particles which is hydrated prior to injection into the disc.

### Claim 8 (depends on 7)

The method of claim 7, wherein the dried nucleus pulposus particles are a volume of particles of a size of 400 microns or less and configured to pass through the small gauge needle when hydrated.

### Claim 9 (depends on 7)

The method of claim 7, wherein the regenerative disc material has whole cells intermixed with the volume of nucleus pulposus particles after hydration to form the flowable mixture regenerative disc material with whole cells.

### Claim 10 (depends on 9)

The method of claim 9, wherein the whole cells are derived from bone marrow.

### Claim 11 (depends on 1)

The method of claim 1, wherein the tissue regeneration material comprises:
a micronized material of nucleus pulposus;
a biological composition made from a mixture of mechanically selected allogeneic biologic material derived from bone marrow having non-whole cellular components including vesicular components and active and inactive components of biological activity, cell fragments, cellular excretions, cellular derivatives, and extracellular components; and
wherein the mixture is compatible with biologic function.

### Claim 12 (depends on 11)

The method of claim 11, wherein the mixture of mechanically selected material derived from bone marrow further includes non-expanded whole cells.

### Claim 13 (depends on 12)

The method of claim 12, wherein the combination of non-whole cell components with a select number of the non-expanded cells sustains pluripotency in the cells.

### Claim 14 (depends on 13)

The method of claim 13, wherein the select number of the non-expanded cells includes differentiated committed cells and non-differentiated and non-committed cells.

### Claim 15 (depends on 11)

The method of claim 11, wherein the biological composition is predisposed to demonstrate or support elaboration of active volume or spatial geometry consistent in morphology with that of disc tissue.

### Claim 16 (depends on 11)

The method of claim 11, wherein the biological composition extends regenerative resonance that compliments or mimics disc tissue complexity.

### Claim 17 (depends on 11)

The method of claim 11, wherein the mixture is treated in a protectant or cryoprotectant prior to preservation or cryopreservation.

### Claim 18 (depends on 17)

The method of claim 17, wherein the protectant or cryoprotectant creates a physical or electrical or chemical gradient or combination thereof for tissue regeneration.

### Claim 19 (depends on 12)

The method of claim 12, wherein the bone marrow mixture which is derived from a cadaver has separation-enhanced cell vitality including one or more of the following:
separating the cells heightens their vitality, reversing “arrest” of donors, responsive molecular coupling, matrix quest in neutralizing inflammation or satience by balancing stimulus for repair.

### Claim 20 (depends on 17)

The method of claim 17, wherein the protectant or cryoprotectant is a polyampholyte.

### Claim 21 (depends on 17)

The method of claim 17, wherein the cryopreservation occurs at a temperature that is sub-freezing.

### Claim 22 (depends on 21)

The method of claim 21, wherein the cryopreservation temperature is from 0 degrees C. to −200 degrees C.

### Claim 23 (depends on 11)

The method of claim 11, can be organelle fragments.

### Claim 24 (depends on 11)

The method of claim 11, wherein active an inactive components of biological activity can be extants of the human metabolome.

### Claim 25 (depends on 1)

The method of claim 1, further comprises the method of making the tissue regeneration material comprising the steps of:
collecting, recovering and processing bone marrow from a cadaver donor;
mechanically separating cellular and non-cellular components of bone marrow from cadaverous bone;
concentrating by centrifugation and filtering;
separation by density gradient centrifugation;
collecting cells or non-cellular components or combinations thereof of predetermined density;
washing the cells or non-cellular components or combinations thereof to create a mixture;
quantifying cell concentration not to exclude zero;
suspending to a predetermined concentration in a polyampholyte cryoprotectant;
freezing the mixture at a predetermined controlled rate; and
packaging micronized nucleus pulposus having particles in the size range of less than 300 μm either within the mixture or separate.

### Claim 26 (depends on 25)

The method of claim 25 further includes the steps of:
thawing the mixture;
diluting the thawed mixture in saline without spinning; and
injecting the diluted mixture with or without the micronized nucleus pulposus being intermixed into a disc of a patient.

### Claim 27 (depends on 26)

The method of claim 26, wherein the step of thawing the mixture occurs at a temperature of 37 degrees C. for 2 to 3 minutes in a warm water bath.

### Claim 28 (depends on 11)

The method of claim 11, wherein the micronized material has particles sized less than 400 microns.

### Claim 29 (depends on 28)

The method of claim 28, wherein the micronized material is formed as a powder.

### Claim 30 (depends on 29)

The method of claim 29, wherein the powder is dried either hypothermically using a cold desiccation technique or by standard commercial freeze drying technology.

### Claim 31 (depends on 11)

The method of claim 11, wherein the nucleus pulposus is taken from cadaver vertebrae.

### Claim 32 (depends on 31)

The method of claim 31, wherein the cadaver vertebrae are human vertebrae.

### Claim 33 (depends on 11)

The method of claim 11, wherein the micronized material of nucleus pulposus has dehydrated proteoglycan molecules and other preserved growth factors.

### Claim 34 (depends on 11)

The method of claim 11, wherein the micronized material has been dried and aseptically stored in a container.

### Claim 35 (depends on 34)

The method of claim 34, wherein the micronized material when rehydrated has a high viscosity.

### Claim 36 (depends on 35)

The method of claim 35, wherein the material exhibits the viscosity at which the rehydrated material is flowable as injectable through a small bore cannula.

### Claim 37 (depends on 36)

The method of claim 36, wherein the rehydrated material is stored in a syringe or other injectable device for insertion into a damaged disc to be treated.

### Claim 38 (depends on 1)

The method of claim 1 further comprises the method of manufacturing a tissue regeneration material comprising the steps of:
aseptic recovery of cadaveric spine segments from T9 to L5;
removal of the discs by cutting between the cancellous bone and vertebral endplate junction;
removing the normal nucleus pulposus;
freeze drying the nucleus pulposus from multiple disc segments;
placing the freeze dried material into a cryomill; and
placing the micronized disc material into a sterile container for later use

### Claim 39 (depends on 1)

The method of claim 1 further comprises a treatment method for damaged viable disc regeneration comprising the steps of:
rehydrating the micronized material into a flowable mixture;
placing the material in a container for injection or a syringe either prior to or during or after the step of hydration;
injecting the hydrated material through a cannula into the disc space to be regenerated.
